



Magnolia now offers a comprehensive test for 26 upper and lower respiratory pathogens. With a turnaround time of 24 hours or less, clinicians are able to use an evidence-based diagnosis to increase the value of care provided to their patients.

Key Benefits:

- Reduce unnecessary antibiotic use
- Increase patient satisfaction
- Decrease time to optimal therapy
- Reduce cost associated with unnecessary prescriptions and urgent care visits

Key Statistics:

- Viral Respiratory Infections cost our healthcare system \$40 billion annually.¹
- Influenza and pneumonia are the eighth leading cause of mortality among adults in the United States and result in more than 60,000 deaths annually.²
- PCR-based testing for community-acquired pneumonia increases pathogen detection rates upwards of 86% (compared to 30-40%).²

Magnolia Respiratory Panel Pathogens:





- Influenza A
- Influenza B
- Human rhinovirus
- Human adenovirus
- RSV A/B
- Enterovirus
- Coronavirus NL63
- Coronavirus 229E
- Coronavirus OC43
- Parainfluenza 1
- Parainfluenza 2
- Parainfluenza 3
- Parainfluenza 4
- Metapneumovirus A/B
- Bocavirus
- Mycoplasma pneumoniae
- Chlamydia pneumoniae
- Streptococcus pneumoniae
- Staphylococcus aureus
- Klebsiella pneumoniae
- Legionella pneumophila/longbeachae
- Salmonella spp.
- Moraxella catarrhalis
- Bordetella spp.
- Haemophilus influenzae
- Haemophilus influenzae B

1. Fendrick A, et al. (2003) The Economic Burden of Non-Influenza-Related Viral Respiratory Tract Infection in the United States. *Arch Intern Med* 163(4):487-94.

2. Kaysin A, Viera AJ. Community-Acquired Pneumonia in Adults: Diagnosis and Management. *AAFP Home*. <https://www.aafp.org/afp/2016/1101/p698.html>. Published November 1, 2016. Accessed January 1, 2019.



CONTACT US

-  469-759-3325
-  magnoliadx.com
-  972-707-9929
-  Customercare@magnoliadiagnostics.com